The Impact of Prophylactic Salpingo-oophorectomy on Health in Women who carry a BRCA1 or BRCA2 Mutation

作者: Amy Philippa Mary Finch

DOI:

关键词: Hormone replacement therapy (menopause)ObstetricsOvarian cancerGynecologyBreast cancerFallopian tube cancerSexual functionProspective cohort studyPopulationCancerMedicine

摘要: Prophylactic salpingo-oophorectomy, the preventive removal of ovaries and fallopian tubes, is recommended to women who carry a BRCA1 or BRCA2 mutation in order reduce risk breast, ovarian tube cancer. The short long term health quality life effects this procedure are not well understood. We examined actual perceived reduction cancer associated with surgery. impact prophylactic salpingo-oophorectomy on health-related life, psychological distress, worry, menopausal symptoms, sexual function during year following surgery was also evaluated. In our prospective study, an 80% risk. residual for primary peritoneal 0.2% per 4.3% at 20 years after salpingo-oophorectomy. Most accurately their breast However, overestimated, particularly by mutation. Physical mental did decrease surgery; distress similar levels experienced general population. were significantly less worried about surgery, however, subset continued experience significant specific Women underwent when premenopausal worsening vasomotor symptoms decline functioning. Hormone replacement therapy mitigated these but pre-surgical levels. Dyspareunia somewhat alleviated hormone therapy, pleasure not. Satisfaction decision undergo high regardless symptoms. These studies will provide considering information possible

参考文章(252)
Ella Lishinsky, Bella Kaufman, Gila Hornreich, Raphael Catane, Ephrat Levy-Lahad, Amnon Lahad, Mordechai Shohat, Barbara L. Weber, Shlomit Eisenberg, Uziel Beller, David Halle, Founder BRCA1 and BRCA2 mutations in Ashkenazi Jews in Israel: frequency and differential penetrance in ovarian cancer and in breast-ovarian cancer families. American Journal of Human Genetics. ,vol. 60, pp. 1059- 1067 ,(1997)
Barlow Jj, Piver Ms, Sawyer Dm, Familial ovarian cancer: increasing in frequency? Obstetrics & Gynecology. ,vol. 60, pp. 397- 400 ,(1982)
M S Piver, M F Jishi, N Natarajan, Y Tsukada, J M Goldberg, C J Mettlin, Characteristics of familial ovarian cancer: a report of the first 1,000 families in the Gilda Radner Familial Ovarian Cancer Registry. European Journal of Gynaecological Oncology. ,vol. 17, pp. 169- 176 ,(1996)
Jason Klapman, Mokenge P. Malafa, Early detection of pancreatic cancer: why, who, and how to screen. Cancer Control. ,vol. 15, pp. 280- 287 ,(2008) , 10.1177/107327480801500402
D T Bishop, D F Easton, D Ford, Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. American Journal of Human Genetics. ,vol. 56, pp. 265- 271 ,(1995)
Peter Devilee, Fattaneh A. Tavassoli, Pathology and Genetics of Tumours of the Breast and Female Genital Organs World Hhealth Organization Classification of Tumours. ,(2003)
H E Averette, R E Estape, S E Sightler, G M Boike, Ovarian cancer in women with prior hysterectomy : a 14-year experience at the University of Miami Obstetrics & Gynecology. ,vol. 78, pp. 681- 684 ,(1991)
Tucker Ma, Struewing Jp, Ponder Ba, Watson P, Lynch Ht, Easton Df, Prophylactic oophorectomy in inherited breast/ovarian cancer families. Journal of The National Cancer Institute Monographs. pp. 33- 35 ,(1995)
Albert Chudley, Steven A. Narod, Christine Maugard, Charmaine Kim-Sing, Kelly A Metcalfe, André Robideaux, Peter Ainsworth, Parviz Ghadirian, Diane Provencher, William Foulkes, Susan Armel, Doug Horsman, Andrea Eisen, Edmond G. Lemire, Ping Sun, Barry Rosen, Dawna Gilchrist, Amy Finch, Variation in rates of uptake of preventive options by Canadian women carrying the BRCA1 or BRCA2 genetic mutation. Open Medicine. ,vol. 1, ,(2007)
Aron Goldhirsch, John H. Glick, Richard D. Gelber, Alan S. Coates, Hans-Jörg Senn, Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. Journal of Clinical Oncology. ,vol. 19, pp. 3817- 3827 ,(2001) , 10.1200/JCO.2001.19.18.3817